July 8, 2021 • 11:11 am CDT (Precision Vaccinations)
The JAMA Oncology published the results from a cohort study Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer.
On July 8, 2021, this Original Investigation concluded by saying, In this cohort study of 223 cancer patients, the SARS-CoV-2 BNT162b2 vaccine (Pfizer-BioNTech, Comrinaty) appeared to be safe and achieve satisfactory serologic status. There was a pronounced lag in antibody production compared with the rate in noncancer controls. However, seroconversion occurred in most patients after the second vaccine dose.
Moreover, future real-world data are warranted to determine the long-term efficacy of the Pfizer-BioNTech vaccine concerning the type of anticancer treatment.